Objectives: Functional (psychogenic or somatoform) symptoms are common in neurology clinics.
pression, especially if combined with face-toface guidance as so-called guided self-help (GSH). 10 CBT-based GSH has not, however, been evaluated as a treatment for functional neurologic symptoms.
We aimed to test the hypothesis that adding GSH to the usual care (UC) received by neurology outpatients with functional symptoms would produce a greater improvement in their self-rated health at 3 months after randomization. We also measured symptoms (physical and psychological), functional illness beliefs, health anxiety, and satisfaction with care at 3 and 6 months. Study design and setting. The study was a 2-arm parallel group randomized controlled trial with patient-rated outcome assessment at 3 months and at 6 months. The trial was conducted in 2 regional Scottish National Health Service neurology services (Edinburgh and Glasgow), which together serve a population of approximately 4 million.
Participants and procedures. We included adult neurology outpatients with functional symptoms identified by screening and referred by their neurologist. Between February 2006 and January 2007, we asked neurologists to rate the symptoms of all patients attending general neurology clinics on the following 4-point Likert-type scale: To what extent do you think this patient's symptoms are explained by organic disease?-not at all, somewhat, largely, or completely-and to refer those with functional symptoms (defined as not at all or only somewhat explained by organic disease) to the trial.
We gave referred patients a study information leaflet and an appointment with a trial doctor, at which written consent was obtained. We excluded patients who 1) were judged to be unable to use GSH (significant cognitive impairment or unable to comprehend English), 2) required specialist psychiatric care (severe psychiatric disorder, currently engaged in psychological or psychiatric treatment, or suicide risk), or 3) had headache as their only symptom (because of the key role of addressing analgesic use in their management).
Randomization.
We randomly assigned consenting patients in a 1:1 ratio to either usual care alone or usual care plus GSH. The randomization sequence was computer-generated and stratified on 2 potentially prognostic variables: neurology service (Edinburgh or Glasgow) and symptoms being not at all or at least somewhat explained by organic disease. The trial doctors obtained the treatment allocation only after providing each patient's data to a remote telephone-based randomization system. Treatment conditions. All participants received UC, which was enhanced by communicating the psychiatric diagnoses made during the assessment (for example, major depression) to the pa-tient's primary care doctor and neurologist. We recorded all treatments received during the trial when outcome data were collected. Participants could not be masked to treatment allocation. UC alone. Participants allocated to UC received UC alone. UC plus CBT-based GSH. We offered all participants allocated to GSH a CBT-based self-help workbook and face-to-face guidance sessions in its use, in addition to UC. CBT is a form of psychological treatment that aims to improve patients' physical symptoms, emotional state, and functioning by helping them to understand and, where necessary, change how they think about and respond to their symptoms and life situation. We developed the workbook using existing CBT-based self-help manuals for depression and anxiety and refined it by piloting. 11, 12 The book explained functional symptoms 9, 13 as changes in nervous system functioning that were influenced by psychological and behavioral factors rather than simply psychogenic factors. 14 It also included 1) an explanation of how functional symptoms are diagnosed, 2) a description of common symptoms and the associated anatomy, physiology, and psychology, and 3) selfmanagement techniques, such as ways to reduce unhelpful thinking about and coping with symptoms. More details are available from the authors.
Guidance sessions (maximum 4 half-hour sessions over 3 months) were given face-to-face (by telephone if the patient was unable to attend the hospital) by either a nurse or a psychologist (both trained in CBT) in accordance with a guidance manual. A neuropsychiatrist (A.C.) provided regular supervision. We audio-recorded all guidance sessions; a randomly selected 10% sample was independently rated for adherence to the manual. Data collection. We collected baseline data before randomization and outcome data at 3 and 6 months after randomization using mailed self-report questionnaires. Participants were reminded by telephone, and, if necessary, their questionnaire data were obtained by dictation to a research assistant who was blind to treatment allocation.
Measures. Baseline data. Demographic and clinical variables
(age, sex, marital status, employment status, nature, and duration of symptoms) were recorded at interview.
Psychiatric diagnoses were made using a semi-structured interview based on the PRIME-MD. 15 Symptom burden was measured using the Patient Health Questionnaire (with sexual and menstrual items removed) to leave 13 items. 16 Physical function was measured using the subscale of the Medical Outcomes Short Form 12-Item Scale (SF-12). 17 Anxiety and depression were measured using the Hospital Anxiety and Depression Scale. 18 Health anxiety was assessed using items from the Whiteley Index 19 ; participants were asked to answer yes or no to the following questions: Do you think there is something seriously wrong with your body? Do you worry a lot about your health?
Illness beliefs were assessed using items from the Illness Perceptions Questionnaire 20 ; participants were asked to indicate how much they agreed with the following on a 5-point Likert scale (strongly disagree to strongly agree): My symptoms are likely to be permanent rather than temporary. My symptoms are a mystery to me.
Outcome data. Self-rated global improvement measured at 3 months using the clinical global improvement scale (CGI) was the primary outcome. This 5-point Likert scale asked participants to rate their general health as much worse, worse, unchanged, better, or much better, compared with how it was at the time of their original appointment at the neurology clinic. This simple scale has been found to correlate with other specific outcomes in this population. 6 The change in presenting symptoms scale (CPS) was measured using a similar scale, on which participants rated the "symptoms for which you came to the clinic."
Treatment received during the trial was determined by asking participants to list all treatments (talking treatments, medication, and other treatments) they had received. For participants allocated to GSH, the number and duration of guidance sessions were recorded by the therapists.
Participants' satisfaction with the overall quality of their treatment (poor, fair, very good, or excellent) and whether they would recommend it to a friend (definitely not, probably not, possibly, or definitely) was assessed using 4-point Likert scales.
Finally, measures of symptom burden, physical function anxiety, and depression were repeated at the outcome assessments. 
Statistical analysis.
A sample size of 130 was planned on the basis of feasibility and provided 80% power at the 5% significance level (2-sided) to detect a common odds ratio (OR) of 2.5, using a proportional odds model. We performed all the analyses on an intention-to-treat basis, including all randomly assigned patients for whom outcome data were available. We adjusted for the service the patient attended, for how explained the symptoms were by disease ("not at all" or "somewhat"), and, where relevant, for the baseline score. The primary efficacy evaluation was at 3 months. Because the data on the primary outcomes were virtually complete (98%), only a complete case analysis was performed. Analysis of the CGI score was based on comparing the randomized groups using a proportional odds model (which calculates the OR using all the scale response categories). 21 For this analysis, participants who reported feeling worse or much worse and better or much better were combined to give 3 outcome groupings per treatment arm (worse, same, or better). This analysis was repeated for the CGI at the 6-month follow-up and also for CPS and patient satisfaction at 3 and 6 months.
For the quantitative outcome measures, the group means were compared using analysis of covariance. Differences between the groups in health anxiety questions were analyzed using binary logistic regression to estimate the odds of endorsing them.
We made no correction for clustering by therapist because the main component of treatment was a standardized manual. Indeed, because the majority (72%) of participants receiving GSH were seen by one therapist, there was little scope to investigate or adjust for a clustering effect. No formal adjustment was made for multiplicity of outcome measures because there was a prespecified primary outcome measure (CGI score at 3 months), and the p values for all other outcomes were interpreted conservatively. RESULTS Sample. Of the 3,057 patients who had their symptoms rated by a neurologist, 492 (16.1%) received a diagnosis of functional symptoms. The neurologists referred 291 of these patients, of whom 170 attended for assessment. Of the 127 patients who were recruited, 63 were randomly assigned to UC and 64 to GSH (figure 1).
Baseline characteristics. Table 1 shows characteristics of the participants at baseline. Seventy percent were women, and the mean age was 43 years. An average of 2.5 symptoms was recorded per patient; the 10 most common symptoms are shown in table 1. Nearly half of the participants reported that they were not working for health reasons, and three-fourths reported symptoms of longer than 1 year in duration. Generalized anxiety (38%) and panic (56%) were the most common psychiatric diagnoses. There were no substantial differences in baseline variables between treatment arms.
Treatment received. Participants in both treatment arms attended their primary care doctor; a minority were seen for repeat appointments by the neurologist. Eight participants had received a new prescription for antidepressants by 3 months and an additional 6 by 6 months. UC alone. Of 14 new prescriptions for antidepressants, 11 were for participants in the UC group. One participant receiving UC received CBT outside the trial.
GSH. All participants allocated to GSH were given the workbook, and 62 of 64 (97%) received at least one session of guidance in its use. The first 46 were allocated to one therapist and the remaining 18 to the other. The mean number of sessions given was 3 (range 0 -4) of average duration 30 minutes. Only 5 sessions were con- Health anxiety (concern that there is something seriously wrong with your body and worry a lot about your health) was lower in those allocated to GSH. There were, however, no effects on beliefs about health (symptoms are permanent and symptoms are a mystery). Satisfaction with treatment received at 3 months was much greater for participants allocated to GSH. Secondary outcomes at 6 months are reported in table 3. The adjusted common OR for an improved outcome with GSH on the CGI was 1.45 (95% CI 0.75-2.83) and was no longer statistically significant ( p ϭ 0.27). However, participants allocated to GSH continued to report a greater improvement in presenting symptoms (adjusted common OR 2.31, 95% CI 1.18 -4.51; p ϭ 0.014) and now physical function (adjusted mean difference 11.05, 95% CI 3.03-19.06; p ϭ 0.007). Health anxiety was no longer less in those allocated to GSH, but the belief that the symptoms are permanent was. Satisfaction with treatment at 6 months remained much greater for those allocated to GSH.
No unintended adverse effects of treatment were observed. DISCUSSION We found that addition of GSH to UC improved subjective health at 3 months more than UC alone did. The treatment effect was of moderate size with a 13% difference between treatment arms in participants rating themselves as better or much better (corresponding to a NNT of 8). Taking these results together with the greater improvements in presenting symptoms, reduced symptom burden, less health anxiety and greater satisfaction with care, the chronicity of the patients' illnesses, and the simplicity of the intervention and its safety, we believe that the observed treatment effect is clinically useful.
At the 6-month follow-up, the additional effect of GSH on improvement in subjective health was smaller (OR 1.45) and no longer statistically significant. There was, however, a greater improvement in presenting symptoms, less belief in the symptoms being permanent, greater satisfaction with care, and a clinically significant 11-point difference on the SF-12 physical functioning scale. 22 The smaller treatment effect on the primary outcome at follow-up suggests that future studies should test the effect of adding a maintenance phase to the GSH guidance.
There are limitations to this study. Although the sample of patients recruited was identified by screening and therefore more likely to be representative of patients attending neurology clinics than of referrals, the proportion reported as having functional symptoms (16%) was smaller and the severity of their ill-
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Self-rated change in overall health (CGI). Relative frequencies and treatment group at 3 and 6 months ness was greater than expected from previous surveys. 5, 23 This finding suggests that neurologists were selecting which patients to refer. We included patients with a variety of symptoms, and the resulting heterogeneity potentially obscures the size of the treatment effect for individual symptoms. Although there is always a lack of certainty that symptoms are definitely functional and not indicative of organic disease, follow-up evidence from the same services suggests that the diagnosis is rarely wrong. 23 Even if organic disease subsequently emerges, as long as GSH is given as a supplement to rather than as a replacement for UC, no harm is likely to result. The UC given to participants in the trial was enhanced by informing the patients' primary care doctors of the outcome of the psychiatric assessment. Although the clinicians who provided GSH were trained in CBT, we know from adherence ratings of session recordings that they provided only guidance and not CBT.
Because participants allocated to GSH received a complex intervention of workbook, attention, and face-to-face guidance sessions, we cannot identify which of these components was the most important. Our outcomes were measured by self-report, reflecting the subjective nature of the problems we were treating. However, the nature of the treatments meant that participants could not be blinded to their allocation, which could have potentially biased their outcome ratings. Finally, the follow-up period was relatively short, given the chronicity of the patients' illnesses. Future effectiveness studies should examine longer-term outcomes as well as costs.
There are many uncertainties about how best to manage this large and important group of patients. First, what should the treatment be? Whereas intensive psychologically oriented CBT is effective for patients with functional symptoms who seek it, 24, 25 we have found that CBT based on a functional explana- tion can be acceptable to relatively unselected neurology patients. Second, where should treatment be delivered? Although most previous studies have included only patients willing to attend mental health services, 26 -28 this trial shows that treatment can be provided in neurology clinics. 29 Third, who should deliver treatment? CBT delivered by trained therapists is expensive to provide, and therapists may simply not be available. Primary care physicians can be trained to provide psychological treatment for functional symptoms, but this has been found to be of limited efficacy, in part because of the difficulty of delivering it in routine practice 30, 31 ; treatment by medical specialists is likely to have similar limitations. This trial suggests that CBT given as GSH offers a potentially widely available, effective, and cost-effective treatment for the large number of neurology patients with functional symptoms. This trial provides initial evidence that CBTbased GSH for neurology patients with functional symptoms is feasible to deliver and acceptable to the patients and produces better outcomes than UC alone, at least in the short term. It therefore offers a novel and potentially useful first step in improving the management of functional symptoms. Further development of this form of treatment to increase its effectiveness and to evaluate its cost-effectiveness is required. We also hope that this trial encourages others in interdisciplinary treatment research for patients with this problem.
